The program is open to Ophthalmologists who are members of the POS and we invite Ophthalmologists who are non-members.  

Intent and Overview

More efficient detection and treatment of ophthalmic conditions and diseases are constantly being discovered and acted upon. This program is based upon the need to apprise local physicians of the diagnostic modalities and treatments being utilized at teaching centers and ophthalmologic offices across the country.

Meeting Objectives

This course will highlight the recent developments regarding diagnosis as well as medical and surgical therapy of common eye diseases. The participant should get a comprehensive review of the most current concepts in the management of ophthalmology by experts across the breadth of the field. For example, clinical trials and other evidence in the peer-reviewed literature over the past few years have changed the approach to managing cataract including IOL technology and femtosecond laser cataract surgery, corneal disease including dry eye disease, keratoplasty, and collagen cross linking, glaucoma and minimally invasive glaucoma surgical devices, as well as diabetic retinopathy, macular degeneration, and retinal vein occlusions. This course also includes legislative updates as it pertains to Ophthalmologists and their practice. At the conclusion of this meeting, participants should be able to:

• Update their knowledge of diagnosis and treatment of common and rare ophthalmic diseases.
• Identify major advances in key areas of cutting-edge research and technology in Ophthalmology
• Identify (appropriately) subsets of patients who may benefit from new treatment paradigms, diagnostic testing, or surgical interventions.
• Develop a differential diagnosis for a refractive surprise
• Understand the leading factors which predict an individual’s health outcome
• Enhance the ability to recognize the key clinical features of retinoblastoma and utilize appropriate diagnostic techniques, including imaging and genetic testing, to confirm diagnosis
• Evaluate current treatment modalities for retinoblastoma, including chemotherapy, focal therapies, and enucleation, to formulate individualized, evidence-based management plans that optimize patient outcomes
• Incorporate new treatment paradigms, diagnostic approaches, and surgical techniques into current clinical practice
• Review, modify, and hone surgical skills and approaches to specific eye problems and clinical situations
• Develop strategies to identify and address their own individual professional practice gaps
• Gain an understanding of the diagnostic process and the significance of diagnostic errors
• Document care in a timely manner, including the thought process underlying management of various situations, such as ruling out differential diagnoses, treatment plans, etc.
• Review the 10 most important innovations that will lead us into the next decade of Cataract surgery
• Describe the tools needed for cataract surgeons to be successful in the future
• Explain why a patient may be unhappy with their surgical outcome despite achieving 20/20 vision.

Accreditation Statement

Allegheny General Hospital is accredited by the Accredited Council for Continuing Medical Education to provide continuing medical education for physicians.

Certification Statement

Allegheny General Hospital designates this live activity for a maximum of 6.75 AMA Category 1 Credits™. Application has been submitted for CME with  final credit hours  posted once determined. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Joint Provided Activities Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Allegheny General Hospital and the Pittsburgh Ophthalmology Society.

Faculty Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), and the policy of Allegheny General Hospital, presenters are asked to indicate if they have any relationship, which, in the context of their presentation, could be perceived as a real or apparent conflict of interest (e.g., ownership of stock, honoraria or consulting fees). Any such relationship will be disclosed to the audience and consideration will be given to possible influence of their presentations. 

Pamela P. Rath, MD  - No Disclosures

Kendall Donaldson, MD, MS –  Dr. Donaldson has disclosed she is a Consultant for the following:

Alcon, Lumenis, Allergan/Abbvie, Oyster Point, Johnson and Johnson, Rayner, LensAR, BVI, SUN, Quidel, Zeiss, Dompe, Eyevance, Glaukos, Bausch and Lomb, Tarsus, PRN, Kala, iOR, Science Based Health

Ralph Eagle, Jr. MD – Dr. Eagle has disclosed he is a stockholder in Merck.

Peter Netland, MD, PhD –TBD

Mark Rolain, MD – No Disclosures

Any identified conflicts have been mitigated.

2025 ANNUAL MEETING AND BANQUET*

REGISTRATION FEES

Physician Member, Annual Meeting Only - NO Annual Banquet      $385

Physician Member | Annual Meeting & Annual Banquet                   $425

($40 banquet fee for member included) 

Physician Non-Member of POS - Annual Meeting Only                    $485

Resident | Fellow Member of POS - Annual Meeting and Banquet   $295

Resident | Fellow Member of POS - Annual Meeting Only                 $260

Annual Banquet Guest Fee - (Member Bringing a Guest)                 $  95

(*Registrants will be able to add guests when registering.

Guest fee will be added to final total of registration fee')

___________________________

*Only those registering for the Annual Meeting may register for the Annual Banquet.

Registration Fee includes:

•  Continental Breakfast, Luncheon and Refreshments

•  CME Credits (6.75 AMA PRA Category 1 Credits™)

• Additional fee for the Thursday Evening Annual Banquet

• OMIC DISCOUNT: OMIC insureds who attend the OMIC lectures will receive a 5% discount on their premium, applied upon renewal. Insureds who are also a member of a society with which OMIC has an educational alliance may be able to earn an additional 5% discount. Please consult our website for details: OMIC Partners  or contact OMIC Risk Management at 415-202-4652.